NewLink gets $1M Ebola study contract

The U.S. Defense Threat Reduction Agency (DTRA) issues a $1M letter contract to NewLink Genetics (NASDAQ:NLNK) subsidiary BioProtection Systems Corp. for studies supporting the advancement of an Ebola vaccine licensed from the Public Health Agency of Canada. The contract will fund the pre-clinical toxicology studies that will enable an IND application and also includes the manufacture of clinical materials.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs